Trulieve Faces Lawsuit Over Employee Firings in Florida

Dec.14.2022
Trulieve Faces Lawsuit Over Employee Firings in Florida
Trulieve, a multi-state marijuana operator based in Florida, faces a collective lawsuit for allegedly not providing adequate notice prior to employee layoffs.

Trulieve, a multi-state cannabis operator headquartered in Florida, recently terminated some of its employees in Gadsden County. This resulted in affected workers filing a collective lawsuit alleging that the company did not provide sufficient notice before their termination.


Trulieve, a Florida-based cannabis company, operates two cultivation sites in Quincy and a processing plant on Midway Island in Gadsden County. The company has not disclosed the number of employees who have been terminated but has stated that the move is aimed at reducing layoffs as the company continues to grow, according to the Tallahassee Democrat.


According to Trulieve spokesperson Steve Vancore, affected employees have been offered alternative jobs at the company's other factories in Jefferson and Madison counties. Those employees who were ultimately not able to secure another position will receive severance pay.


Vancore informed Democratic lawmakers in Tallahassee that the layoffs ultimately stemmed from Trulieve's acquisition of Harvest Health and Recreation, which is based in Arizona.


We merged and acquired Harvest a year ago," Vancore told the news media. "This was part of our consolidation strategy as we continue to develop in areas of redundancy and inefficiency. When you have 9,000 employees, this is indeed a measure to improve efficiency.


Last week, employees affected by layoffs filed a class-action lawsuit against Trulieve, alleging that the company failed to provide the required Worker Adjustment and Retraining Notification (WARN) Act notice regarding their termination.


According to Democrats in Tallahassee, the lawsuit alleges that if a company lays off "50 or more employees (excluding any part-time employees) at a single worksite within any 30-day period," it must provide a notice under the WARN Act.


According to a report by the Tampa Bay Times, the lawsuit was originally filed by attorney Tiffany Cruz on behalf of Langel O'Neil, who worked at Trulieve's Quincy facility. The plaintiff is seeking monetary compensation equivalent to the total amount of unpaid wages, salaries, commissions, bonuses, accrued vacation pay, accrued sick pay, and other benefits within 60 days after termination. This has been reported in the media.


Trulieve has contested these allegations, according to Tallahassee attorney and partner at Stearns Weaver Miller, Glenn Burhans Jr., who told the news media that Trulieve "has complied with all state and federal laws regarding the reduction of force.


In possible scenarios, Trulieve offers affected employees new positions at the same location or other locations within the area," he told the Tampa Bay Times. "If relocation is not feasible or not accepted, employees will receive severance pay.


In another statement provided to the news media, Trulieve expressed its commitment to the northwest region of Florida and highlighted the construction of a 750,000-square-foot facility in Jefferson County by the company.


According to a statement released by the company to the Tampa Bay Times, Trulieve has approximately 9,000 employees in the United States and is currently hiring for "additional positions in various fields".



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

 FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
FDA Begins Review of 22nd Century’s VLN MRTP Renewal Applications
The U.S. Food and Drug Administration (FDA) has initiated scientific review of renewal applications for 22nd Century Group’s VLN reduced-nicotine cigarettes under the Modified Risk Tobacco Product (MRTP) pathway, with current authorizations set to expire in December 2026.
News
May.13
Special Report | Russian Vape Compromise Faces First Hurdles
Special Report | Russian Vape Compromise Faces First Hurdles
Russia’s regional vape-ban model is facing early legal and political tests, as Perm Krai moves ahead before federal legislation is fully adopted. The case highlights uncertainty over regional authority, concerns from business groups about market fragmentation, and the risk that pressure against regional bans could revive calls for a stricter nationwide prohibition.
Industry Insight
May.28
FDA Posts Environmental Assessment for Nicotine Pouches, May Influence Future PMTA Reviews
FDA Posts Environmental Assessment for Nicotine Pouches, May Influence Future PMTA Reviews
The U.S. Food and Drug Administration released a programmatic environmental assessment covering nicotine pouches and other oral nicotine products, concluding that their overall environmental impact is generally minimal.
Regulations
May.22
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Innovation, Insights and Networking: NUBIZ Brings the Global NGP Industry Together in Dortmund
Innovation, Insights and Networking: NUBIZ Brings the Global NGP Industry Together in Dortmund
The market for next-generation products is expanding rapidly, with vapes, e-cigarettes, pouches, snus and heat-not-burn products among the industry’s most innovative segments. As part of InterTabac, NUBIZ provides a central platform for reduced-risk tobacco and nicotine products, bringing together global leaders and newcomers from 15 to 17 September. The show combines market insights, product comparisons, networking, a high-level conference programme and exclusive side events.
Jun.03
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan announced that it will launch “TEREA Blossom Pearl,” a new tobacco stick for IQOS ILUMA, on May 11. The new product will expand the TEREA lineup to 27 variants. It features a capsule menthol flavor with strawberry and subtle herbal notes and is priced at JPY 620, or about USD 4.14 based on an assumed rate of 1 JPY = 0.00668 USD. The exchange-rate source should be verified and added.
Apr.28 by 2FIRSTS.ai